TD Private Client Wealth LLC Has $10.27 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

TD Private Client Wealth LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,908 shares of the company’s stock after buying an additional 5,501 shares during the period. TD Private Client Wealth LLC’s holdings in Johnson & Johnson were worth $10,267,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Hudson Value Partners LLC lifted its position in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock worth $5,648,000 after buying an additional 1,022 shares in the last quarter. Proficio Capital Partners LLC raised its holdings in shares of Johnson & Johnson by 22.0% in the 4th quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company’s stock valued at $2,885,000 after purchasing an additional 3,594 shares during the period. Raymond James Financial Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at about $1,339,878,000. Finally, OFI Invest Asset Management bought a new position in Johnson & Johnson in the 4th quarter valued at about $1,260,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on JNJ shares. Bank of America reduced their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Benchmark raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Barclays decreased their price target on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Finally, Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Trading Down 0.5%

Shares of Johnson & Johnson stock opened at $155.23 on Tuesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company’s 50-day simple moving average is $153.67 and its 200-day simple moving average is $154.24. The firm has a market cap of $373.49 billion, a price-to-earnings ratio of 17.27, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s payout ratio is currently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.